Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(3):579–583. doi: 10.1054/bjoc.1999.0967

Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction

J Kupryjánczyk 1,4, A Dansonka-Mieszkowska 1, T Szymánska 1, G Karpínska 4, A Rembiszewska 1, M Rusin 3, R Konopínski 1, E Kraszewska 2, A Timorek 5, D W Yandell 6, J Stelmachów 5
PMCID: PMC2363315  PMID: 10682669

Abstract

Changes in cell survival contribute to tumour development, influence tumour biology and its response to chemotherapy. p53 gene alterations should negatively affect apoptosis by impaired p53-dependent apoptotic response. We looked for associations between spontaneous apoptosis, p53 gene mutation, p53 protein accumulation, growth fraction, bcl-2 expression and histological parameters in 64 ovarian, four tubal and three peritoneal carcinomas. Apoptotic cells were detected with the TUNEL method. p53 gene variants were detected by the single-strand conformation polymorphism and were sequenced directly. P53, Ki-67 and bcl-2 protein expressions were detected immunohistochemically. A weighed multiple logistic regression model was applied. Apoptotic index (Al) ranged 0.02–0.18 (mean 0.11); proliferation index (PI) ranged 3–90% (mean 54%). p53 gene mutations were present in 51, p53 protein accumulation in 46, and diffuse bcl-2 expression in 29 of 71 tumours. The AI was positively associated with the presence of p53 gene mutation (P = 0.011). However, the PI included into the analysis did positively influence the AI (P = 0.02) and diminished the association with p53 gene mutation (P = 0.082). The AI was negatively associated with good histological differentiation (P = 0.0006), the serous tumour type (P = 0.002), and diffuse bcl-2 expression (P = 0.025). Strong bcl-2 expression was associated with endometrioid tumour type (P = 0.002). FIGO stage and p53 protein accumulation were the only parameters that influenced overall survival time. Thus, our results suggest that histological tumour type and grade are major determinants of spontaneous apoptosis in ovarian carcinomas;p53 alterations do not adversely but rather positively affect spontaneous apoptosis by increasing growth fraction. This, in turn, suggests p53-independency of spontaneous apoptosis in ovarian carcinomas. © 2000 Cancer Research Campaign

Keywords: apoptosis, p53 gene mutation, p53 protein accumulation, growth fraction, bcl-2, ovarian cancer, survival

Full Text

The Full Text of this article is available as a PDF (72.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amundson S. A., Myers T. G., Fornace A. J., Jr Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene. 1998 Dec 24;17(25):3287–3299. doi: 10.1038/sj.onc.1202576. [DOI] [PubMed] [Google Scholar]
  2. Barber H. R., Sommers S. C., Synder R., Kwon T. H. Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer. Am J Obstet Gynecol. 1975 Mar 15;121(6):795–807. [PubMed] [Google Scholar]
  3. Bellamy C. O. p53 and apoptosis. Br Med Bull. 1997;53(3):522–538. doi: 10.1093/oxfordjournals.bmb.a011628. [DOI] [PubMed] [Google Scholar]
  4. De Feudis P., Debernardis D., Beccaglia P., Valenti M., Graniela Siré E., Arzani D., Stanzione S., Parodi S., D'Incalci M., Russo P. DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br J Cancer. 1997;76(4):474–479. doi: 10.1038/bjc.1997.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Diebold J., Baretton G., Felchner M., Meier W., Dopfer K., Schmidt M., Löhrs U. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol. 1996 Mar;105(3):341–349. doi: 10.1093/ajcp/105.3.341. [DOI] [PubMed] [Google Scholar]
  6. Evan G., Littlewood T. A matter of life and cell death. Science. 1998 Aug 28;281(5381):1317–1322. doi: 10.1126/science.281.5381.1317. [DOI] [PubMed] [Google Scholar]
  7. Henriksen R., Strang P., Wilander E., Bäckström T., Tribukait B., Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol. 1994 Jun;53(3):301–306. doi: 10.1006/gyno.1994.1138. [DOI] [PubMed] [Google Scholar]
  8. Herod J. J., Eliopoulos A. G., Warwick J., Niedobitek G., Young L. S., Kerr D. J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996 May 1;56(9):2178–2184. [PubMed] [Google Scholar]
  9. Hirai Y., Kaku S., Teshima H., Shimizu Y., Chen J. T., Hamada T., Fujimoto I., Yamauchi K., Sakamoto A., Hasumi K. Clinical study of primary carcinoma of the fallopian tube: experience with 15 cases. Gynecol Oncol. 1989 Jul;34(1):20–26. doi: 10.1016/0090-8258(89)90098-x. [DOI] [PubMed] [Google Scholar]
  10. Klemi P. J., Pylkkänen L., Kiilholma P., Kurvinen K., Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer. 1995 Oct 1;76(7):1201–1208. doi: 10.1002/1097-0142(19951001)76:7<1201::aid-cncr2820760716>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  11. Kupryjanczyk J., Bell D. A., Dimeo D., Beauchamp R., Thor A. D., Yandell D. W. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol. 1995 Apr;26(4):387–392. doi: 10.1016/0046-8177(95)90138-8. [DOI] [PubMed] [Google Scholar]
  12. Kupryjańczyk J., Thor A. D., Beauchamp R., Merritt V., Edgerton S. M., Bell D. A., Yandell D. W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961–4965. doi: 10.1073/pnas.90.11.4961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Liebermann D. A., Hoffman B., Steinman R. A. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene. 1995 Jul 6;11(1):199–210. [PubMed] [Google Scholar]
  14. Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993 Sep 24;74(6):957–967. doi: 10.1016/0092-8674(93)90719-7. [DOI] [PubMed] [Google Scholar]
  15. McMenamin M. E., O'Neill A. J., Gaffney E. F. Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival. Mol Pathol. 1997 Oct;50(5):242–246. doi: 10.1136/mp.50.5.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Miyashita T., Harigai M., Hanada M., Reed J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994 Jun 15;54(12):3131–3135. [PubMed] [Google Scholar]
  17. Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., Reed J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994 Jun;9(6):1799–1805. [PubMed] [Google Scholar]
  18. Miyashita T., Reed J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995 Jan 27;80(2):293–299. doi: 10.1016/0092-8674(95)90412-3. [DOI] [PubMed] [Google Scholar]
  19. Qin X. Q., Livingston D. M., Kaelin W. G., Jr, Adams P. D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10918–10922. doi: 10.1073/pnas.91.23.10918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Reed J. C. Double identity for proteins of the Bcl-2 family. Nature. 1997 Jun 19;387(6635):773–776. doi: 10.1038/42867. [DOI] [PubMed] [Google Scholar]
  21. Righetti S. C., Della Torre G., Pilotti S., Ménard S., Ottone F., Colnaghi M. I., Pierotti M. A., Lavarino C., Cornarotti M., Oriana S. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996 Feb 15;56(4):689–693. [PubMed] [Google Scholar]
  22. Röhlke P., Milde-Langosch K., Weyland C., Pichlmeier U., Jonat W., Löning T. p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin Oncol. 1997;123(9):496–501. doi: 10.1007/BF01192204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tai Y. T., Lee S., Niloff E., Weisman C., Strobel T., Cannistra S. A. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol. 1998 Aug;16(8):2583–2590. doi: 10.1200/JCO.1998.16.8.2583. [DOI] [PubMed] [Google Scholar]
  24. Wagner A. J., Kokontis J. M., Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev. 1994 Dec 1;8(23):2817–2830. doi: 10.1101/gad.8.23.2817. [DOI] [PubMed] [Google Scholar]
  25. Wu X., Levine A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3602–3606. doi: 10.1073/pnas.91.9.3602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yamasaki F., Tokunaga O., Sugimori H. Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol Oncol. 1997 Sep;66(3):439–448. doi: 10.1006/gyno.1997.4783. [DOI] [PubMed] [Google Scholar]
  27. Yonish-Rouach E., Grunwald D., Wilder S., Kimchi A., May E., Lawrence J. J., May P., Oren M. p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol. 1993 Mar;13(3):1415–1423. doi: 10.1128/mcb.13.3.1415-1423.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Zindy F., Eischen C. M., Randle D. H., Kamijo T., Cleveland J. L., Sherr C. J., Roussel M. F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998 Aug 1;12(15):2424–2433. doi: 10.1101/gad.12.15.2424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. de Stanchina E., McCurrach M. E., Zindy F., Shieh S. Y., Ferbeyre G., Samuelson A. V., Prives C., Roussel M. F., Sherr C. J., Lowe S. W. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 1998 Aug 1;12(15):2434–2442. doi: 10.1101/gad.12.15.2434. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES